Abstract
Overview
Introduction
NICE is one of the most advanced cost effectiveness assessment bodies
operating in the major pharmaceutical markets. Since it was established it has
had an increasing impact on the availability of new drugs in England and
Wales, but has also generated considerable attention globally.
Scope
- Overview of the UK pricing and reimbursement system and the role NICE
plays in it
- Analysis of the key issues facing NICE and the measures being taken to
rectify them
- Discussion of case studies to illustrate the effect of and response to key
NICE rulings
Highlights
NICE plays a key role in the UK healthcare system although it does not
currently assess all new drug approvals. It' s impact is also felt outside the
UK as organizations and indeed individual physicians in other countries also
monitor its conclusions.
A variety of stakeholders have input into the NICE topic selection process
including patients, physicians and the pharmaceutical industry. To date cancer
drugs have accounted for the largest number of completed assessments.
Reasons to Purchase
- Understand how NICE assessments impact the pricing and reimbursement
environment in England and Wales
- Gain insight into the key issues with NICE assessments and the changes
which are being used to tackle them
- Benchmark the impact and response to the outcome of key NICE assessments
View Cart
